CDKN2A and adenocarcinoma: p16 is useful as part of a panel of immunohisto-chemical markers for distinguishing primary ovarian tumors from metastases and, when diffusely positive, can suggest the cervix as a potential primary site for metastatic adenocar-cinomas of unknown origin [12].